CHA Biotech
Financials
Valuation Metrics
CHA Biotech's Market Cap is ₩7949B. At end of 2025 it was ₩1.4T. Ranked #356 of 2,419 in KR market (top 15%), #114 of 1,638 on KOSDAQ (top 7%), #9 of 95 in Health Care Equipment & Services (top 9%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 794.92B KRW | KR#356/2,419 Sec#9/95 |
| Revenue | 1.31T KRW | KR#346/2,419 Sec#2/95 |
| Net Income | -16.43B KRW | KR—/2,419 Sec—/95 |
| Total Assets | 2.86T KRW | KR#248/2,419 Sec#2/95 |
| Net Assets | 1.03T KRW | KR#290/2,419 Sec#3/95 |
| Employees | 334 | KR#720/2,419 Sec#19/95 |
| Value | ||
| P/B | 0.77x | KR#1,204/2,419 Sec#24/95 |
| P/S | 0.61x | KR#1,036/2,419 Sec#13/95 |
| FCF Yield | -27.61% | KR—/2,419 Sec—/95 |
| Profitability | ||
| ROE | -1.60% | KR#1,663/2,419 Sec#56/95 |
| ROA | -0.57% | KR#1,628/2,419 Sec#53/95 |
| Op. Margin | -5.68% | KR#1,877/2,419 Sec#59/95 |
| Revenue Growth | 13.93% | KR#723/2,419 Sec#39/95 |
| Financial Health | ||
| Debt Ratio | 178.44% | KR#2,031/2,419 Sec#88/95 |
| Total Debt | 1.29T KRW | KR#174/2,419 Sec#1/95 |
| FCF | -219.51B KRW | KR#2,174/2,419 Sec#85/95 |
| Cash | 303.36B KRW | KR#193/2,419 Sec#1/95 |
| Current Ratio | 0.89x | KR#1,851/2,419 Sec#83/95 |
| Dividend | ||
| Div. Yield | 0.11% | KR#1,363/2,419 Sec#39/95 |
| Div. Growth | -67.82% | KR—/2,419 Sec—/95 |
| Performance | ||
| 1Y Return | -24.60% | KR#1,491/2,419 Sec#44/95 |
| 1M Return | 5.69% | KR#743/2,419 Sec#43/95 |
| From 52W High | -64.30% | KR#2,048/2,419 Sec#78/95 |
| 1Y MDD | -67.55% | KR#1,863/2,419 Sec#65/95 |
| Trading | ||
| Volume | 136,867 shares | KR#684/2,419 Sec#25/95 |
| Trading Value | 1.18B KRW | KR#711/2,419 Sec#25/95 |
| Foreign Own. | 7.88% | KR#563/2,419 Sec#16/95 |
| Per Share | ||
| EPS | -177 KRW | KR—/2,419 Sec—/95 |
| BPS | 11,044 KRW | KR#930/2,419 Sec#18/95 |
Company Info
CHA Biotech, established in 2002, engages in umbilical cord blood banking, stem cell research and cell therapy development, and anti-aging services. Through its major subsidiaries, the company operates pharmaceutical, global CDMO, and global medical network businesses, leveraging an ecosystem-based clinical and new drug development platform. Revenue generation is expected from advanced regenerative medicine treatment sales and global out-licensing. It is also strengthening its global network by establishing the world's largest Cell and Gene Therapy (CGT) manufacturing facility. CHA Biotech is headquartered in Gangnam-gu, Seoul.